Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
Anteris Technologies Global Corp. has obtained full regulatory approval from France's ANSM to begin patient enrollment for the global pivotal PARADIGM Trial evaluating its DurAVR® Transcatheter Heart Valve in patients with severe aortic stenosis. This milestone supports the company's clinical and regulatory strategy by enabling trial sites in Franc…